Research ArticleBone

JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function

See allHide authors and affiliations

Science Translational Medicine  12 Feb 2020:
Vol. 12, Issue 530, eaay4447
DOI: 10.1126/scitranslmed.aay4447

Article Information

vol. 12 no. 530

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication June 28, 2019
  • Accepted for publication January 8, 2020
  • .

Author Information

  1. Susanne Adam1,2,
  2. Nils Simon1,2,
  3. Ulrike Steffen1,2,
  4. Fabian T. Andes1,2,
  5. Carina Scholtysek1,2,
  6. Dorothea I. H. Müller1,2,
  7. Daniela Weidner1,2,
  8. Darja Andreev1,2,
  9. Arnd Kleyer1,2,
  10. Stephan Culemann1,2,3,
  11. Madelaine Hahn1,2,
  12. Georg Schett1,2,
  13. Gerhard Krönke1,2,
  14. Silke Frey1,2,*, and
  15. Axel J. Hueber1,2,,
  1. 1Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3–Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany.
  2. 2Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany.
  3. 3Nikolaus Fiebiger Center of Molecular Medicine, Universitätsklinikum Erlangen and Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  1. *Corresponding author. Email: silke.frey{at}uk-erlangen.de
  • These authors jointly supervised this work.

  • Present address: Sektion Rheumatologie, Sozialstiftung Bamberg, Buger Str. 80, 96049 Bamberg, Germany.

Altmetric

Article usage

Article usage: February 2020 to February 2020

AbstractFullPdf
Feb 20204240622345

Stay Connected to Science Translational Medicine